Index RUT
P/E -
EPS (ttm) -0.08
Insider Own 1.82%
Shs Outstand 14.35M
Perf Week 0.41%
Market Cap 213.73M
Forward P/E -
EPS next Y -
Insider Trans -
Shs Float 14.25M
Perf Month 0.14%
Income -1.18M
PEG -
EPS next Q -
Inst Own 64.18%
Short Float 5.43%
Perf Quarter 11.35%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -0.55%
Short Ratio 7.70
Perf Half Y 20.26%
Book/sh 1.31
P/B 11.27
EPS next Y -
ROA -6.05%
Short Interest 0.77M
Perf Year 25.17%
Cash/sh 1.30
P/C 11.32
EPS next 5Y 5.60%
ROE -6.22%
52W Range 11.45 - 15.89
Perf YTD 9.77%
Dividend Est. -
P/FCF -
EPS past 5Y 56.22%
ROI -6.30%
52W High -7.36%
Beta 1.43
Dividend TTM -
Quick Ratio 43.50
Sales past 5Y 0.00%
Gross Margin -
52W Low 28.56%
ATR (14) 0.17
Dividend Ex-Date Dec 13, 2019
Current Ratio 43.50
EPS Y/Y TTM 27.67%
Oper. Margin 0.00%
RSI (14) 63.84
Volatility 0.61% 0.69%
Employees -
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 4.00
Target Price 4.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 53.22%
Payout -
Rel Volume 0.00
Prev Close 14.72
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings Mar 07 AMC
Avg Volume 100.47K
Price 14.72
SMA20 0.11%
SMA50 5.25%
SMA200 15.06%
Trades
Volume 0
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-07-16 Downgrade
JP Morgan
Overweight → Neutral
May-27-16 Initiated
Robert W. Baird
Neutral
$8
Dec-23-15 Reiterated
Mizuho
Buy
$16 → $13
Oct-27-15 Reiterated
Oppenheimer
Outperform
$13 → $15
Apr-21-15 Reiterated
Mizuho
Buy
$13 → $16
Oct-10-14 Resumed
Oppenheimer
Outperform
$9 → $11
Jul-08-14 Resumed
Brean Capital
Buy
$16
Jun-20-14 Reiterated
Oppenheimer
Outperform
$10 → $8.50
Aug-09-13 Reiterated
Oppenheimer
Outperform
$12 → $10
Jun-25-13 Initiated
Mizuho
Buy
$12
May-08-12 Initiated
Oppenheimer
Outperform
$12
Show Previous Ratings
Mar-08-24 08:51AM
Mar-07-24 04:30PM
Feb-13-24 04:18PM
Dec-29-23 01:48PM
Nov-02-23 04:30PM
07:02AM
Loading…
Aug-15-23 07:02AM
Aug-03-23 04:30PM
Jul-03-23 08:24AM
May-04-23 05:00PM
Apr-19-23 07:02AM
Mar-09-23 04:40PM
Jan-23-23 08:44AM
Dec-28-22 10:15PM
Dec-13-22 06:44AM
Dec-05-22 09:00AM
06:56AM
Loading…
Nov-17-22 06:56AM
Nov-16-22 11:28AM
Nov-10-22 05:11AM
Nov-09-22 10:13AM
09:04AM
Nov-03-22 04:45PM
Aug-16-22 08:11AM
Aug-04-22 05:00PM
Aug-03-22 11:49AM
08:30AM
Jul-06-22 07:07AM
May-05-22 04:30PM
Mar-09-22 04:30PM
Jan-27-22 04:48AM
Dec-06-21 07:22AM
05:00PM
Loading…
Nov-04-21 05:00PM
Sep-06-21 09:50AM
Aug-05-21 04:30PM
Jun-08-21 05:31AM
Jun-07-21 02:10PM
May-28-21 08:00AM
Mar-10-21 06:00PM
Dec-10-20 02:10AM
Dec-03-20 07:46AM
Nov-29-20 12:12PM
Nov-05-20 08:20AM
Aug-07-20 08:20AM
Aug-05-20 08:33AM
May-07-20 06:10PM
Apr-02-20 08:30AM
Feb-07-20 11:14AM
Dec-22-19 07:44PM
Dec-03-19 09:15AM
08:45AM
Oct-28-19 06:04AM
(American City Business Journals)
Sep-24-19 04:45PM
Sep-19-19 03:23PM
09:00AM
Aug-26-19 11:27AM
(American City Business Journals)
09:00AM
Aug-22-19 08:30AM
Aug-16-19 09:15AM
Jul-25-19 08:30AM
May-31-19 07:34AM
06:21AM
(American City Business Journals)
May-30-19 04:05PM
May-10-19 07:30AM
May-06-19 01:46PM
May-03-19 05:43PM
Apr-18-19 03:07PM
Apr-16-19 04:15PM
Apr-12-19 01:57PM
Apr-09-19 05:50PM
Apr-08-19 10:12AM
Apr-05-19 08:29AM
(Simply Wall St.) -16.41%
07:48AM
Apr-04-19 05:58PM
(American City Business Journals)
04:15PM
Mar-07-19 09:06AM
Mar-06-19 07:00AM
Feb-12-19 07:35AM
Feb-11-19 09:39AM
Jan-28-19 10:19PM
(Thomson Reuters StreetEvents)
Dec-10-18 05:00PM
Nov-09-18 10:31AM
08:45AM
Nov-08-18 10:17AM
(American City Business Journals)
Nov-07-18 06:45AM
Nov-06-18 01:44PM
Nov-05-18 07:55AM
Oct-31-18 04:05PM
Oct-24-18 11:19AM
Oct-19-18 10:48AM
07:46AM
06:00AM
Oct-16-18 07:30AM
Oct-11-18 05:16PM
Sep-20-18 07:00AM
Sep-06-18 10:35AM
06:50AM
Sep-05-18 12:06PM
(Thomson Reuters StreetEvents)
Sep-04-18 10:07AM
Aug-16-18 08:00AM
Aug-08-18 10:20AM
Aug-07-18 08:18AM
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Andersen Eric Director Dec 28 '23 Buy 13.35 857 11,441 534,008 Dec 28 04:05 PM Andersen Eric Director Dec 26 '23 Buy 13.15 48,693 640,313 533,151 Dec 28 04:05 PM Andersen Eric Director Dec 07 '23 Buy 12.85 101,050 1,298,472 1,735,600 Dec 11 04:05 PM Andersen Eric Director Nov 17 '23 Buy 12.50 300 3,750 1,659,216 Nov 20 06:59 PM Andersen Eric Director Nov 14 '23 Buy 12.50 50,170 627,125 1,658,981 Nov 16 05:09 PM Andersen Eric Director Nov 09 '23 Buy 12.19 9,975 121,618 1,577,704 Nov 13 04:05 PM Andersen Eric Director Nov 08 '23 Buy 12.13 13,823 167,701 1,569,894 Nov 13 04:05 PM CROCKER GARY L See Remarks Aug 11 '23 Buy 12.43 2,000 24,865 133,105 Aug 14 04:06 PM CROCKER GARY L See Remarks Aug 10 '23 Buy 12.52 2,000 25,039 133,105 Aug 14 04:06 PM Andersen Eric Director Aug 08 '23 Buy 12.00 87,057 1,044,327 1,565,111 Aug 09 04:06 PM Andersen Eric Director Aug 07 '23 Buy 12.00 134,493 1,614,414 1,496,680 Aug 09 04:06 PM Andersen Eric Director Mar 21 '23 Buy 11.52 160,590 1,849,997 1,412,044 Mar 22 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite